13D·WATCH Activist + Insider Intelligence Live feed Blog About Pilot
SCHEDULE Filed 2025-02-19 Event 2025-02-13 SEC 0001398344-25-003088 →

111 Equity Group Matinas BioPharma Holdings, Inc. MTNB

Stake: 3.61% Shares: 183,639 CUSIP: 576810303 Class: Common Stock

Item 4 — Purpose of Transaction

The Reporting Persons engaged in discussions with management and may engage in discussions with, management, the board of directors, and/or other shareholders of the Issuer, and/or other relevant parties (including, without limitation, service providers) concerning the business, capitalization, financial condition, operations, strategy and future plans of the Issuer, and potential avenues to enhance stockholder value, as well as other matters related to the Issuer. Such evaluations and discussions may materially affect, and result in, among other things, the Reporting Persons: (1) modifying their ownership of the shares, including, without limitation, the purchase or sale of shares in the open market or through privately negotiated transactions of otherwise; (2) exchanging information with the Issuer pursuant to appropriate confidentiality or similar agreements; (3) proposing changes in the Issuer's operations, governance or capitalization; or (4) proposals or assisting in formulating plans or proposals that involve one or more of the types of transactions specified in sub-items (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons may at any time reconsider and change their plans or proposals relating to the foregoing. Other than as described in this Schedule 13D, the Reporting Persons do not have any present plan or proposal that would relate to or result in any of the matters set forth in sub-items (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons retain the right to change their investment intent at any time and there is no assurance the Reporting Persons will continue discussion or evaluation of any transactions or that any transaction will be pursued and, if pursued, will be consummated. Moreover, any actions described in this Item 4 that the Reporting Persons might undertake may be made at any time and from time to time and such determinations will be dependent upon the Reporting Persons' review of numerous factors, including, but not limited to, an ongoing evaluation of the Issuer's business, financial condition, operations and prospects; price levels of the Issuer's securities; general market, industry and economic conditions; and other future developments affecting the Issuer.

Cross-References

Insider Activity (last 365d)
0 transactions
0 buys · 0 sales · 0 awards/exercises
Issuer Cluster
1 13D/G filings on this issuer
0 other filings besides this one
Filer Track Record
1 filings by this filer
0 other filings in the data moat
Short Interest · settle 2026-03-31
DTC 1.00
8,751 shares short · +21.8% vs prior

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. $1,500/mo. Pilots welcome.

Request a pilot →